Source: International Congress 2017 – Scientific year in review



Rating:

Share or cite this content

Citations should be made in the following way:
J. Aerts (ROTTERDAM, Netherlands). Drug development: news from “hot” early stage clinical trials: personalised immunotherapy for lung cancer. International Congress 2017 – Scientific year in review

Member's Comments

No comment yet.

Related content which might interest you: Clinical trials in advanced stage lung cancer: A survey of patients‘ opinion about their treatment Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients Year: 2010 Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing? Source: Eur Respir J 2014; 44: 1011-1022 Year: 2014 Immunotherapy with nivolumab in NSCLC: single center experience after one year clinical practice Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches Source: Virtual Congress 2021 – Thoracic oncology Year: 2021 Impact of COPD on prognosis of lung cancer: the prespective of immunotherapy treatment Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Commentary: The ERS/ESTS clinical guidelines for evaluating fitness for radical treatment for lung cancer Source: Breathe 2008; 6: 141-145 Year: 2009 Current place and future of immunotherapy in lung cancer Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies? Year: 2016 Systemic therapy. non small cell lung cancer stage I and II: treatment standards and new development Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Lung disease induced by newer therapies for lung cancer: an update Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006 Targeted therapies for lung cancer: how did the game begin? Source: Breathe 2016; 12: 177-179 Year: 2016 Slow-growing lung cancer as an emerging entity: from screening to clinical management Source: Eur Respir J 2013; 42: 1706-1722 Year: 2013 Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors Year: 2008 Enrolment in clinical trials enhances the survival benefit provided to lung cancer patients Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Checkpoint inhibition (neo-)adjuvant therapy in early stage lung cancer: the oncological evidence Source: Virtual Congress 2021 – Hot topics in thoracic oncology Year: 2021 Current neoadjuvant/adjuvant treatment for advanced stage lung cancer Source: International Congress 2014 – PG19 Surgery for advanced stage lung cancer Year: 2014 Biomarkers for non-small cell lung cancer (NSCLC) treatment: examples and unmet needs, a clinical perspective Source: International Congress 2014 – From bench to bedside: biomarkers and biobanking for lung cancer in 2014 Year: 2014 Novel aspects in lung cancer pathology: how does it help for selecting chemotherapy? Source: Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician Year: 2010 Issues other than tissue: non-invasive biomarkers of early stage lung cancer Source: Virtual Congress 2020 – Will the pulmonologist still play a role in the management of screen-detected pulmonary nodules? Year: 2020 The clinical benefit of personalised medicine in lung cancer Source: International Congress 2014 – Understanding the benefit of current personalised medicine platforms Year: 2014